Johnson & Johnson (JNJ) Current Deferred Tax Assets (2009 - 2015)

Johnson & Johnson's (JNJ) quarterly Current Deferred Tax Assets came in at $3.6 billion in Q3 2015, down 5.77% year-on-year from $3.8 billion in Q3 2014, and down 3.14% quarter-over-quarter from $3.7 billion in Q2 2015.

Johnson & Johnson (JNJ) Current Deferred Tax Assets (2009 - 2015) Analysis & Trends

Johnson & Johnson has disclosed Current Deferred Tax Assets across 7 years of filings, most recently posting $3.6 billion for Q3 2015.

  • Current Deferred Tax Assets for Q3 2015 came in at $3.6 billion, down 5.77% year-over-year; the trailing twelve-month figure through Sep 2015 was $3.6 billion (down 5.77% YoY), and the FY2014 annual result was $3.6 billion, down 1.11% from the prior year.
  • Current Deferred Tax Assets came in at $3.6 billion for Q3 2015 at Johnson & Johnson, down from $3.7 billion in the prior quarter.
  • In the past five years, Current Deferred Tax Assets ranged from a high of $4.1 billion in Q2 2014 to a low of $2.2 billion in Q1 2011.
  • The 5-year median for Current Deferred Tax Assets is $3.3 billion (2012), against an average of $3.2 billion.
  • Across the five-year window, Current Deferred Tax Assets declined 20.37% in 2011 and soared 35.17% in 2012, its largest moves.
  • Johnson & Johnson's Current Deferred Tax Assets stood at $2.5 billion in 2011, then advanced by 26.57% to $3.1 billion in 2012, then climbed by 14.91% to $3.6 billion in 2013, then decreased by 1.11% to $3.6 billion in 2014, then climbed by 1.09% to $3.6 billion in 2015.
  • The last three Current Deferred Tax Assets figures came in at $3.6 billion (Q3 2015), $3.7 billion (Q2 2015), and $3.5 billion (Q1 2015), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Sep 27, 2015 3.61 Bn
Sep 27, 2015 3.61 Bn
Jun 28, 2015 3.72 Bn
Jun 28, 2015 3.72 Bn
Mar 29, 2015 3.52 Bn
Mar 29, 2015 3.52 Bn
Dec 28, 2014 3.57 Bn
Dec 28, 2014 3.57 Bn
Sep 28, 2014 3.83 Bn
Sep 28, 2014 3.83 Bn
Jun 29, 2014 4.10 Bn
Jun 29, 2014 4.10 Bn
Mar 30, 2014 3.92 Bn
Mar 30, 2014 3.92 Bn
Dec 29, 2013 3.61 Bn
Dec 29, 2013 3.61 Bn
Sep 29, 2013 3.49 Bn
Sep 29, 2013 3.49 Bn
Jun 30, 2013 3.28 Bn
Jun 30, 2013 3.28 Bn